Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.43 |
| ▸ | DUT | P33316 | 2/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19052706 | 0.80 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19052786 | 0.80 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19053005 | 0.80 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10470783 | 0.80 | DUT (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL22902121 | 0.73 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12280146 | 0.73 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13664001 | 0.73 | LMNA (0.50) | SLC29A1P2RY2 | |
| SCHEMBL8885780 | 0.72 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14928767 | 0.72 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12157247 | 0.71 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2007047793-A2 | CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | REV1, NSUN2, ORC3 | SLC28A1 281/4885SLC28A2 240/4885SLC29A1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.